Statin and MTHFR C677T Polymorphism in Patients with Cardiovascular Diseases

Creative Commons License

Izmirli M., BACAKSIZ A., ALPTEKİN D., UYSAL Ö., Kilic U.

BEZMIALEM SCIENCE, vol.2, no.1, pp.38-41, 2014 (ESCI, TRDizin) identifier

  • Publication Type: Article / Article
  • Volume: 2 Issue: 1
  • Publication Date: 2014
  • Doi Number: 10.14235/bs.2014.311
  • Journal Name: BEZMIALEM SCIENCE
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.38-41
  • Open Archive Collection: AVESIS Open Access Collection
  • Bezmialem Vakıf University Affiliated: Yes

Abstract

Objective: Cardiovascular disease (CVD) is the leading cause of death worldwide. The methylenetetrahydrofolate reductase (MTHFR) gene, located on the short (p) arm of chromosome 1 at position 36.3 (1p36.3), might be a possible risk factor for the pharmacogenetics in CVD. A common polymorphism in MTHFR (C677T, Ala -> Val) decreases this enzyme activity and increases the homocysteine concentrations, predisposing one to heart disease. Alternatively, statins, cholesterol-reducing agents, are also used to reduce the homocysteine blood concentrations; the aim of the present study was to evaluate how the genotype frequencies of the MTHFR C677T polymorphism, namely rs1801133, change in the cardiovascular system in patients treated with statin.